Jiangsu Nhwa Pharmaceutical Co., LTD
Símbolo: 002262.SZ
SHZ
25.16
CNYPrecio de mercado actual
23.9060
Ratio PER
2.4589
Ratio PEG
25.35B
Capitalización MRK
- 0.00%
Rendimiento DIV
Jiangsu Nhwa Pharmaceutical Co., LTD (002262-SZ) Estados Financieros
Balance de situación
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 13635.22 | 3493.9 | 2984.2 | 2666 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 5823.3 | 1335 | 1452 | 1058.4 | |||||||||||||||||||
balance-sheet.row.net-receivables | 4452.03 | 1091.7 | 937.3 | 757.7 | |||||||||||||||||||
balance-sheet.row.inventory | 2592.65 | 628.6 | 716.3 | 604.3 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 94.68 | 40.3 | 12.6 | 15.1 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 20774.58 | 5254.6 | 4650.4 | 4043.2 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 5602.51 | 1539.5 | 1303.7 | 1158.3 | |||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 1083.69 | 276.2 | 223.8 | 167.5 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 1083.69 | 276.2 | 223.8 | 167.5 | |||||||||||||||||||
balance-sheet.row.long-term-investments | -1914.2 | 157.3 | -1333.4 | -928 | |||||||||||||||||||
balance-sheet.row.tax-assets | 218.31 | 58.3 | 37.5 | 30.7 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | 3137.07 | 42.3 | 1599.7 | 1225.5 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | 8127.38 | 2073.6 | 1831.3 | 1654 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 28901.96 | 7328.2 | 6481.7 | 5697.2 | |||||||||||||||||||
balance-sheet.row.account-payables | 1056.28 | 216.3 | 255.7 | 267.2 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 380.84 | 136.8 | 50.6 | 63 | |||||||||||||||||||
balance-sheet.row.tax-payables | 542.85 | 84.1 | 143.6 | 125.7 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 57.51 | 0.2 | 42.1 | 47.9 | |||||||||||||||||||
Deferred Revenue Non Current | 223.83 | 53.9 | 58 | 63.6 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 40.67 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 892.5 | 434.5 | 426.8 | 2.2 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 329.6 | 50.2 | 103 | 111.5 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 130.84 | 35.6 | 41.9 | 47.7 | |||||||||||||||||||
balance-sheet.row.total-liab | 3568.94 | 864.2 | 897 | 793.5 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.common-stock | 4030.35 | 1007.6 | 1007.6 | 1007.6 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 18875.34 | 4813 | 3978.4 | 3366.1 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2478.66 | 611.2 | 617.6 | 528.3 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 21.03 | 2.3 | 18.7 | 18.7 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 25405.37 | 6434.1 | 5622.2 | 4920.7 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 28901.96 | 7328.2 | 6481.7 | 5697.2 | |||||||||||||||||||
balance-sheet.row.minority-interest | -126.22 | -24 | -37.5 | -17 | |||||||||||||||||||
balance-sheet.row.total-equity | 25279.15 | 6410.1 | 5584.8 | 4903.7 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 28901.96 | - | - | - | |||||||||||||||||||
Total Investments | 3909.1 | 1492.3 | 118.6 | 130.4 | |||||||||||||||||||
balance-sheet.row.total-debt | 512.6 | 172.6 | 92.8 | 110.9 | |||||||||||||||||||
balance-sheet.row.net-debt | -7299.32 | -1986.4 | -1439.4 | -1496.7 |
Estado de tesorería
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 1074.77 | 1036.9 | 880.4 | 798 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 9.99 | 175.1 | 148.7 | 135.1 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -23.2 | -4 | 0.5 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -528.7 | 4 | 2.5 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | -144.64 | -178.6 | -160.6 | -251.1 | |||||||||||||||||||
cash-flows.row.account-receivables | -199.06 | -199.1 | -155.3 | -122.9 | |||||||||||||||||||
cash-flows.row.inventory | 54.43 | 54.4 | -128.2 | -205.9 | |||||||||||||||||||
cash-flows.row.account-payables | 0 | -33.9 | 126.9 | 77.1 | |||||||||||||||||||
cash-flows.row.other-working-capital | -0.01 | 0 | -4 | 0.5 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | -49.47 | 569 | -7.5 | 16.1 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 890.65 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -348.07 | -374 | -327.8 | -206.1 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 1.16 | 1.4 | 0.1 | 0.2 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -6453.5 | -6453.5 | -5527.5 | 0.3 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 6518.29 | 6490.5 | 32.4 | 34.5 | |||||||||||||||||||
cash-flows.row.other-investing-activites | -313.73 | 0 | 5133.9 | -221.4 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -595.85 | -335.6 | -688.9 | -392.5 | |||||||||||||||||||
cash-flows.row.debt-repayment | -65 | -25 | -48 | -38 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0.5 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -0.5 | |||||||||||||||||||
cash-flows.row.dividends-paid | -206.97 | -201.5 | -202.7 | -102.3 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 15.5 | -1.1 | 10 | 12.9 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -215.97 | -210.2 | -240.8 | -127.4 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.53 | 0.4 | 0.9 | -1.1 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 105.47 | 626.7 | -67.7 | 180 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 7750.42 | 2158.9 | 1504.5 | 1572.2 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 7644.95 | 1532.2 | 1572.2 | 1392.2 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 890.65 | 1050.5 | 861 | 701.1 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -348.07 | -374 | -327.8 | -206.1 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 542.57 | 676.6 | 533.3 | 495 |
Fila de la Cuenta de Resultados
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 5182.87 | 4973.5 | 4298.5 | 3935.7 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 1479.99 | 1460.4 | 1020.5 | 897.3 | |||||||||||||||||||
income-statement-row.row.gross-profit | 3702.89 | 3513.1 | 3278.1 | 3038.3 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 571.7 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 48.23 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1753.34 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | -22.02 | -25.5 | 159 | 126.2 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 2586.71 | 2443.5 | 2312.2 | 2116 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 4066.7 | 3903.9 | 3332.7 | 3013.3 | |||||||||||||||||||
income-statement-row.row.interest-income | 19.62 | 23.8 | 25.5 | 17.7 | |||||||||||||||||||
income-statement-row.row.interest-expense | 4.89 | 4.2 | 4.9 | 5.1 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1753.34 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 64.73 | 89.4 | -13.6 | -10.1 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | -22.02 | -25.5 | 159 | 126.2 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 64.73 | 89.4 | -13.6 | -10.1 | |||||||||||||||||||
income-statement-row.row.interest-expense | 4.89 | 4.2 | 4.9 | 5.1 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 89.4 | 175.1 | 159.4 | 173.2 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 1239.16 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 1136.69 | 1069.6 | 1003.5 | 925.9 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 1201.43 | 1159 | 989.9 | 915.8 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 136.17 | 134.4 | 109.5 | 117.8 | |||||||||||||||||||
income-statement-row.row.net-income | 1074.77 | 1036.9 | 900.7 | 797.8 |
Preguntas frecuentes
Cuánto es Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) activos totales?
Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) los activos totales son 7328195368.000.
¿Cuáles son los ingresos anuales de la empresa?
Los ingresos anuales son 2705694560.000.
¿Cuál es el margen de beneficios de la empresa?
El margen de beneficios de la empresa es 0.714.
¿Qué es el flujo de caja libre de la empresa?
El flujo de caja libre es 0.538.
¿Cuál es el margen de beneficio neto de la empresa?
El margen de beneficio neto es 0.207.
¿Cuáles son los ingresos totales de la empresa?
Los ingresos totales son 0.219.
¿Qué es Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) beneficio neto (ingresos netos)?
El beneficio neto (ingresos netos) es 1036918058.000.
¿Cuál es la deuda total de la empresa?
La deuda total es 172558561.000.
¿Cuál es la cifra de gastos de explotación?
Los gastos de explotación son 2443472552.000.
¿Cuál es la cifra de tesorería de la empresa?
La tesorería de la empresa es 1635420861.000.